Editor’s note: This article originally covered a bioRxiv preprint about fetal cerebellar development and medulloblastoma. The subsequent Nature paper was retracted on July 9, 2025, because expert reassessment found insufficient evidence for a proposed cell population central to its conclusions. The authors disagree with the retraction. This revised article corrects our earlier reporting and its overstated treatment implications. Read the retraction notice.
Key Takeaways
- A 2022 study proposed a connection between developing human cerebellar cells and aggressive medulloblastoma.
- The Nature paper was subsequently retracted following concerns about evidence supporting its proposed transitional cerebellar progenitor population.
- Our original coverage overstated what the research established about cancer origins and treatment.
- Medulloblastoma diagnosis and treatment should be understood through independently supported clinical evidence.
Introduction
Understanding how childhood brain tumors develop is an important research goal. Studying the developing human brain can help scientists investigate relationships between normal cell development and cancer.
Our original article reported on research that attempted to make those connections using a human fetal cerebellar cell atlas. However, the resulting Nature publication was later retracted. That development changes how its findings should be presented and interpreted.
This update explains the original proposal, the reason for the retraction, and the corrections to our coverage.
What the Original Study Reported
The researchers analyzed gene activity in individual cells from developing human cerebella and compared those patterns with medulloblastoma samples.
They proposed a population called transitional cerebellar progenitors, or TCPs, and reported similarities between these cells and cell states in aggressive medulloblastoma. The paper also explored molecular mechanisms that might connect developmental programs with tumor growth.
These were research findings and interpretations, rather than proof of improved treatment outcomes in patients. The paper is now retracted and should be identified as such whenever its conclusions are discussed (Luo et al., 2022).
Why Nature Retracted the Paper
Nature’s editors explained that post-publication expert review supported concerns about whether the published data and analyses established the proposed TCP population. This called a key novel conclusion into question. The notice records the authors’ disagreement; it does not allege fraud (Luo et al., 2025).
For readers, the distinction matters: disagreement remains, but the journal has withdrawn the paper. Its central claim should therefore not be presented as an established discovery.
What We Have Corrected
Our earlier headline said the atlas “decodes” the origin and formation of brain cancer. That wording was too definitive. The work concerned particular questions about medulloblastoma, rather than an explanation of brain cancer generally.
The original article also described TCP cells and their role in tumor formation as established findings. This revision identifies them as claims made in the subsequently retracted paper.
We have removed the statement that the study “solved the limitations of rodent models.” Studying human tissue does not, by itself, eliminate the methodological limitations of experimental research.
Finally, we have withdrawn the suggestion that the findings already had clinical applications in developing better treatments. Investigating a possible biological target is different from demonstrating that a treatment is safe and effective in patients.
These corrections address both the retraction and overstatements in our original reporting.
What Remains Established About Medulloblastoma?
Medulloblastoma is a malignant central nervous system tumor that most commonly develops in the cerebellum. Its classification incorporates molecular features, including four widely recognized subgroups: WNT-activated, SHH-activated, Group 3, and Group 4.
Clinical assessment also considers factors such as the patient’s age, whether the disease has spread, and how much tumor remains after surgery. These features help inform risk assessment and treatment decisions (National Cancer Institute, 2024).
That clinical framework does not depend on accepting the disputed TCP population described in the retracted paper.
What Does This Mean for Treatment?
Established treatment can include surgery, chemotherapy, and radiation therapy, with the approach tailored to the patient and tumor characteristics. The National Cancer Institute emphasizes that treatment decisions depend on factors including age, tumor type, location, and remaining tumor after surgery (National Cancer Institute, 2024).
Our original report should not be used as evidence that targeting TCP cells provides an effective treatment. It did not establish a patient benefit, and this correction should not be interpreted as a reason to change an existing treatment plan.
Frequently Asked Questions
Was the Gilmore Health News article itself retracted?
This page has been corrected and updated. The retraction applies to the underlying Nature research paper. We are retaining the page to explain the change in the evidence and correct our earlier coverage.
Does the retraction invalidate all research on fetal brain development and cancer?
No. Other studies must be assessed on their own evidence. However, they cannot automatically be used to validate the specific claims made in this paper.
Why keep the original study in the references?
It remains relevant to documenting what our article originally covered. Its retracted status is explicitly identified, and the retraction notice is included so readers can examine the journal’s explanation.
Final Thoughts
Our original article presented a proposed explanation of medulloblastoma development too confidently. The subsequent retraction makes a clear correction necessary.
Human developmental biology remains an important area of cancer research, but this particular study should no longer be described as having decoded the origin of brain cancer or established a new treatment approach.
References
Luo, Z., Xia, M., Shi, W., Zhao, C., Wang, J., Xin, D., Dong, X., Xiong, Y., Zhang, F., Berry, K., Ogurek, S., Liu, X., Rao, R., Xing, R., Wu, L. M. N., Cui, S., Xu, L., Lin, Y., Ma, W., . . . Lu, Q. R. (2022). Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis [Retracted article]. Nature, 612(7941), 787–794. https://doi.org/10.1038/s41586-022-05487-2
Luo, Z., Xia, M., Shi, W., Zhao, C., Wang, J., Xin, D., Dong, X., Xiong, Y., Zhang, F., Berry, K., Ogurek, S., Liu, X., Rao, R., Xing, R., Wu, L. M. N., Cui, S., Xu, L., Lin, Y., Ma, W., . . . Lu, Q. R. (2025). Retraction note: Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. Nature, 644, 290. https://doi.org/10.1038/s41586-025-09015-w
National Cancer Institute. (2024, August 20). Medulloblastoma: Diagnosis and treatment. https://www.cancer.gov/rare-brain-spine-tumor/tumors/medulloblastoma
Original source record: Our earlier coverage linked to the August 2022 bioRxiv preprint. This link is retained for transparency about the source of the original reporting, rather than as independent confirmation of the disputed findings.